Amaxa Biosystems
Cologne
About Amaxa Biosystems
Amaxa Biosystems GmbH develops and commercializes gene transfer technologies and products. The company offers Nucleofector Technology, a transfection solution which enables the transfer of various substrates, such as DNA, RNA, or peptides into cells. It also offers transfection services; HiFect transfection reagent, the transfection reagent for standard cell lines; antibiotics for the treatment and prevention of mycoplasma and other microbial contaminants; Expression Vectors for the expression of bright fluorescent proteins and individual customer constructs in mammalian cells; and peptide Nucleofection and transfection control solutions. Amaxa Biosystems offers its solutions in Canada, China, Croatia, Greece, Hong Kong, Indonesia, Japan, Korea, Malaysia, Mexico, Portugal, Singapore, Spain, Taiwan, and Turkey. The company was founded in 1998 and is based in Cologne, Germany. As of July 2, 2008, Amaxa Biosystems GmbH operates as a subsidiary of Lonza Group AG.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Funding stage: M&A
- Last round: Series Unknown (Oct 1998)
- Website: amaxa.com
- Phone: 49 221 991990
Industries & Categories
Biotechnology, Genetics, Health Care
Social Profiles
Canonical: https://fsome.com/organization/amaxa-biosystems-846374 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.